Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 in advanced or metastatic urothelial carcinoma
CTR20202417Phase 2Terminated
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in transitional cell carcinoma (TCC), sponsored by Shandong New Era Pharmaceutical. Started Dec 2020; status: terminated.
02
Drugs
rulonilimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20202417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202417.